Effectiveness of Anti-Osteoporotic Medications in the Management of Glucocorticoid-Induced Osteoporosis: A Systematic Review and Network Meta-Analysis on Behalf of the ECTS Clinical Action Group
Clicks: 8
ID: 324231
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
8 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #25 of 91 articles by views in european journal of endocrinology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVE: To evaluate and compare the efficacy of anti-osteoporotic-medications (AOM) for the prevention and treatment of glucocorticoid-induced-osteoporosis (GIOP). DESIGN: Systematic review and network-meta-analysis conducted in accordance with PRISMA-NMA guidelines (ProsperoID:CRD42024502298). METHODS: MEDLINE, Embase, and Web of Science were searched from inception to December 2025 to identify randomized-controlled-trials and comparative-observational-studies evaluating AOM in adults receiving oral glucocorticoids (GC). Outcomes included percentage change in areal bone- mineral-density (aBMD) at the lumbar-spine (primary), femoral-neck, and total-hip. A random effects network-meta-analysis was performed, integrating direct and indirect comparisons across AOM. Certainty of evidence was assessed using the CINeMA framework. RESULTS: Thirty-one studies (28 randomized-controlled-trials and 3 observational-studies) involving 5,260 participants (age-range:29.6-70.6years, 72.5%females) were included. All AOM were superior to placebo or calcium/vitaminD supplementation in increasing lumbar-spine aBMD. Teriparatide demonstrated the greatest efficacy compared with alendronate (effect-size:3.8;95%CI:2.9-4.6), risedronate (4.0;95%CI:2.9-5.1), denosumab (1.5;95%CI:0.1-2.9), and zoledronate (2.4;95%CI:1.1-3.6), while no significant difference was observed with romosozumab (0.3;95%CI:-2.1 to 1.4). Among antiresorptive-medications, zoledronate and denosumab showed greater efficacy than oral bisphosphonates, which demonstrated modest positive effects. In sensitivity analyses restricted to established GIOP, defined as GC users ≥3months, teriparatide and romosozumab remained superior to antiresorptive-medications. Evidence for total-hip and femoral-neck aBMD outcomes was limited by substantial network inconsistency (mostly missing data). Included studies were underpowered to assess difference in fracture outcomes. CONCLUSIONS: This network-meta-analysis demonstrates a clear gradient of efficacy among AOM in GIOP, with anabolic and potent antiresorptive-medications producing the largest gains in lumbar- spine aBMD supporting current ECTS recommendations advocating risk-stratified treatment selection.
| Reference Key |
openalex_W7201886027
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Maria P. Yavropoulou, ter Wee, Anda Mihaela Naciu, Julien Paccou, Athanasios D. Anastasilakis, Chrysoula G. Gialouri, Barbara Hauser, Anne Sophie Sølling, Stella D’Oronzo, Tim Rolvien, Willem F. Lems |
| Journal | european journal of endocrinology |
| Year | 2026 |
| DOI |
10.1093/ejendo/lvag147
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.